Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III prasinezumab study in early-stage Parkinson's disease
2025-522683-32-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Prasinezumab with Placebo (2 arms). Primary endpoint: Time to confirmed motor progression event. Planned start Jan 2026; status: authorised.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-522683-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522683-32-00.